Proposed Combination Products Rule Underestimates the Cost to Industry

International Medical Device Regulatory Monitor
A A
The U.S. Food and Drug Administration’s (FDA) proposed rule on good manufacturing practices (GMPs) for combination products grossly underestimates the burden of applying certain cGMP requirements to device-drug combinations, a device company says.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $20.00